| Ezetimibe | Placebo |
---|---|---|
 | n (%) | n (%) |
Subjects in population | 75 | 77 |
With ≥1 adverse events | 37 (49.3) | 50 (64.9) |
With drug-related adverse events | 3 (4) | 1 (1.3) |
With serious adverse events | 2 (2.7) | 5 (6.5) |
Discontinued due to an adverse event | 1 (1.3) | 1 (1.3) |
Discontinued due to a serious adverse event | 0 (0) | 1 (1.3) |